Caris Life Sciences/LinkedIn
Apr 28, 2025, 16:25
Matthew Oberley: Caris Assure detects CHIP through liquid biopsy and tissue assays
Matthew Oberley, Chief Clinical Officer of Caris Life Sciences, shared a post on LinkedIn by Eric Duncavage, Medical Director of Geneoscopy, Cofactor Genomics and Professor of Pathology and Immunology at Washington University in St. Louis, adding:
“Our liquid biopsy for therapy selection in solid tumors, Caris Assure, directly sequences patient white cells and reports CHIP when present, while our tissue assay can detect CHIP that has infiltrated the tumor.”
Quoting Eric Duncavage’s post, about a paper by Oriol Pich et al. published in NEJM:
“Really nice article in NEJM about tumor-infiltrating clonal hematopoiesis (CHIP) associated with increased risk of disease recurrence or death among patients with non-small cell lung cancer and other solid tumors. CHIP has been associated with so many different diseases at this point and clearly plays an important role in ageing and inflammation. When are we going to start screening patients for CHIP?”
“Tumor-Infiltrating Clonal Hematopoiesis”
Authors: Oriol Pich et al.
More posts featuring Matthew Oberley.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 28, 2025, 16:19
Apr 28, 2025, 15:56
Apr 28, 2025, 15:06
Apr 28, 2025, 14:36
Apr 28, 2025, 14:19
Apr 28, 2025, 13:58
Apr 28, 2025, 13:58
Apr 28, 2025, 13:32